Posaconazole as a Treatment for Rhinosinusitis Mucormycosis
Abstract
Objective: To determine the performance of Posaconazole as a salvage therapy in patients with rhino-orbital-cerebral mucormycosis.Methods
After the ethical committee gave its approval, this cross-sectional study was performed at the Northwest General Hospital & Research Centre, Peshawar, Pakistan. It comprised of data of patients diagnosed with mucormycosis from February 2018 to June 2021. All the patients underwent surgical intervention and were given Posaconazole either as salvage therapy or along with Amphotericin B for the treatment of mucormycosis. Convenient sampling was used and a structured format was used for data collection. SPSS 21 was used for data analysis.Results
Out of the 16 patients, 14 patients improved with Posaconazole with reduction in the lesions. All 16 patients underwent surgical procedure for debridement and given both Amphotericin and Posaconazole. One patient died due to sepsis, and another patient died due to complications of COVID-19 infection. The remaining 14 patients recovered from the surgery, one patient was lost to follow up, and one patient suffered a re-infection, but recovered with Posaconazole.Conclusion
The study highlights the benefit of using Posaconazole either as combined therapy, single use or as a step down therapy for mucormycosis with minimal side effects.Keywords:
Posaconazole, mucormycosis, fungal, infection, rhinosinusitisPublished
2025/03/10
Issue
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com